Celldex Therapeutics (CLDX) Gains from Investment Securities (2017 - 2018)

Celldex Therapeutics (CLDX) posted quarterly Gains from Investment Securities of $26.8 million for Q4 2018, up 22242.98% year-over-year from N/an in Q4 2017, and up 486.34% quarter-over-quarter from -$6.9 million in Q3 2018.

Celldex Therapeutics (CLDX) Gains from Investment Securities (2017 - 2018) Analysis & Trends

Celldex Therapeutics' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $26.8 million for Q4 2018.

  • In Q4 2018, Gains from Investment Securities rose 22242.98% year-over-year to $26.8 million; the TTM figure through Dec 2018 stood at -$1.2 million (down 266.04% YoY), while the FY2023 annual figure was -$1.1 million, down 109.89% from the prior year.
  • Gains from Investment Securities for Q4 2018 stood at $26.8 million, up from -$6.9 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $26.8 million in Q4 2018, with the low at -$13.6 million in Q1 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Celldex Therapeutics 3.29 Bn 2.58 Bn -2.57 Mn

Historic Data

Download Data
DateValue
Dec 31, 2018 26.79 Mn
Dec 31, 2018 26.79 Mn
Sep 30, 2018 -6.94 Mn
Sep 30, 2018 -6.94 Mn
Jun 30, 2018 -7.43 Mn
Jun 30, 2018 -7.43 Mn
Mar 31, 2018 -13.60 Mn
Mar 31, 2018 -13.60 Mn
Dec 31, 2017 -121,000.00
Dec 31, 2017 -121,000.00
Sep 30, 2017 -4.60 Mn
Sep 30, 2017 -4.60 Mn
Jun 30, 2017 1.00 Mn
Jun 30, 2017 1.00 Mn
Mar 31, 2017 3.40 Mn
Mar 31, 2017 3.40 Mn